The term âhistoricâ should be used sparingly. However, today is indeed a historic day in the 111-year history of Fresenius, a global company that began as a pharmacy in Frankfurt. Fresenius Group and Fresenius Medical Care (FMC) are legally separated as of today. We successfully completed the deconsolidation of FMC: Therefore, FMC is no longer a part of the consolidated subsidiaries of Fresenius. The prerequisite for this was FMC's change in legal form to a stock corporation (AG).
Dialysis machines and dialyzers were a part of Fresenius for almost 60 years. FMC was founded in 1996. The dialysis business has contributed an important chapter to the company's history. From now on FMC is heading toward an independent future.
What makes me particularly happy: We have reached this landmark in our #FutureFresenius strategy sooner than planned and with an overwhelming vote from our shareholders at our Extraordinary General Meeting in July. It took less than a year from the announcement to the deconsolidation, which is high-speed. I have compared the complexity of the interdependencies at Fresenius to a Gordian knot. Now we have untied our knot. A big shoutout to many colleagues who worked tirelessly to make this happen.
Why is this historic step so important?
1.  FMC is gaining the freedom that it needs to make the best possible use of its opportunities on the market.
2.  The governance structure is now simplified, enabling more targeted, faster, and agile decisions.
3.  The new structure also gives FMC better access to the capital markets.
Â
The new freedom and greater transparency naturally imply greater responsibility and visibility. The Fresenius Group remains the largest shareholder of FMC with a 32 percent stake. I wish Helen Giza and her team every success on this day of farewell and new beginnings.
We will continue to have much in common in the future: The name Fresenius is a link, as is the aspiration to be economically successful and to offer the highest quality for the benefit of patients worldwide. At Fresenius, we are concentrating on our Operating Companies Fresenius Kabi and Helios Health GmbH and building on our therapy platforms of the future focusing on highly specialized pharmaceutical products, the most precise medical technology, and state-of-the-art patient care. Kabi and Helios are systemically relevant in the healthcare sector with attractive market positions and excellent growth opportunities, being a 22 billion Euro business already today. I am very much looking forward to unleashing the potential of Fresenius in #AdvancingPatientCare â together with a global #TeamFresenius with 190,000 employees in about 80 countries.
Dialysis machines and dialyzers were a part of Fresenius for almost 60 years. FMC was founded in 1996. The dialysis business has contributed an important chapter to the company's history. From now on FMC is heading toward an independent future.
What makes me particularly happy: We have reached this landmark in our #FutureFresenius strategy sooner than planned and with an overwhelming vote from our shareholders at our Extraordinary General Meeting in July. It took less than a year from the announcement to the deconsolidation, which is high-speed. I have compared the complexity of the interdependencies at Fresenius to a Gordian knot. Now we have untied our knot. A big shoutout to many colleagues who worked tirelessly to make this happen.
Why is this historic step so important?
1.  FMC is gaining the freedom that it needs to make the best possible use of its opportunities on the market.
2.  The governance structure is now simplified, enabling more targeted, faster, and agile decisions.
3.  The new structure also gives FMC better access to the capital markets.
Â
The new freedom and greater transparency naturally imply greater responsibility and visibility. The Fresenius Group remains the largest shareholder of FMC with a 32 percent stake. I wish Helen Giza and her team every success on this day of farewell and new beginnings.
We will continue to have much in common in the future: The name Fresenius is a link, as is the aspiration to be economically successful and to offer the highest quality for the benefit of patients worldwide. At Fresenius, we are concentrating on our Operating Companies Fresenius Kabi and Helios Health GmbH and building on our therapy platforms of the future focusing on highly specialized pharmaceutical products, the most precise medical technology, and state-of-the-art patient care. Kabi and Helios are systemically relevant in the healthcare sector with attractive market positions and excellent growth opportunities, being a 22 billion Euro business already today. I am very much looking forward to unleashing the potential of Fresenius in #AdvancingPatientCare â together with a global #TeamFresenius with 190,000 employees in about 80 countries.